Showing results (31-40 of 43) with videos related to
Sort By:
Pageof 5
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1990
Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitorI Tikkanen, K Helin, T Tikkanen, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|April 1, 1997
Inhibition of platelet adhesion and aggregation by E4021, a type V phosphodiesterase inhibitor, in guinea pigsP J Chiu, S Vemulapalli, M Chintala, et al.Journal of Clinical Medicine|September 14, 2024
Ablation Strategies for Persistent Atrial Fibrillation: Beyond the Pulmonary VeinsOmar Baqal, Areez Shafqat, Narathorn Kulthamrongsri, et al.The Journal of Urology|August 24, 1999
The incidence of intersexuality in children with cryptorchidism and hypospadias: stratification based on gonadal palpability and meatal positionM Kaefer, D Diamond, W H Hendren, et al.American Journal of Hypertension|May 1, 1993
Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitorR W Watkins, S Vemulapalli, P J Chiu, et al.The Journal of Pharmacology and Experimental Therapeutics|August 1, 1989
SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive ratsE J Sybertz, P J Chiu, S Vemulapalli, et al.The Journal of Pharmacology and Experimental Therapeutics|August 1, 1981
Antihypertensive and hemodynamic actions of SCH 19927, the R,R-isomer and labetalolT Baum, R W Watkins, E J Sybertz, et al.Journal of Cardiovascular Pharmacology|December 1, 1996
Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitorS Vemulapalli, R W Watkins, M Chintala, et al.Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|March 25, 2026
The blanking interval after atrial fibrillation ablation: time for reassessment with pulsed field energyJuan F Rodriguez-Riascos, Hema S Vemulapalli, James Y Kim, et al.American Heart Journal|June 2, 2021
Estimating the real-world performance of the PROMISE minimal-risk toolM G Nanna, T Y Wang, K Chiswell, et al.Pageof 5